To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

Study Overview

Primary Objective:

-To characterize the pharmacokinetics (PK) of BIVV001 after a single intravenous (IV) administration, as assessed by factor VIII (FVIII) activity determined by the one-stage activated partial thromboplastin time (aPPT) clotting assay, as well as, BIVV001 capture chromogenic Coatest FVIII activity assay

Secondary Objective:

-To assess the safety and tolerability of a single IV dose of BIVV001 in adult patients with type 2N and 3 VWD

Study details

Duration of each part of the study for one participant:

Total study duration: Up to 57 days.

  • Screening: up to 28 days.
  • Up to 29 days of safety observation following the IV BIVV001 dose administration (this period includes PK sampling up to the first 10 days following administration).

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Von Willebrand's Disease (VWD)
  • Age: Between 18 Years - 65 Years
  • Gender: All

Inclusion criteria : 

        -- Male and/or female participant, between 18 and 65 years of age, inclusive at the time of
        informed consent.
          -  The participant has been diagnosed with hereditary type 3 VWD or type 2N VWD as
             documented in historical medical records OR a documented genotype known to produce VWD
             type 3 or 2N VWD.
          -  Type 3 VWD participants are included if they have a medical history of at least 25
             exposure days to VWF and factor VIII-containing coagulation factor concentrates
          -  Type 2N VWD participants are included if the use of DDAVP is deemed insufficient or
             contraindicated, as assessed by the Investigator, or if they have required prior use
             of VWF- and FVIII- containing coagulation factor concentrates.
        Exclusion criteria:
          -  Hereditary or acquired coagulation disorder other than VWD (including qualitative and
             quantitative platelet disorders, and thrombocytopenia < 100,000 cells/uL at Screening)
          -  The participant has a FVIII activity levels >20 IU/dL, at Screening
          -  History or presence of a VWF inhibitor or clinical suspicion of a VWF inhibitor
          -  History of a positive FVIII inhibitor test, defined as ≥0.6 BU/mL (by Nijmegen
             modified Bethesda assay) or a clinical suspicion of a FVIII inhibitor
          -  Positive FVIII inhibitor test, defined as ≥0.6 BU/mL, at Screening
          -  History of hypersensitivity or anaphylaxis associated with any FVIII- or VWF-
             containing product
          -  The participant has received or anticipates receiving systemic immunosuppressive or
             immunomodulatory treatment within 12 weeks prior to Baseline.
          -  The participant requires the use of acetylsalicylic acid, non-NSAID anti-platelets,
             and NSAIDs above the maximum dose product
          -  Patients currently on a prophylaxis regimen for the treatment of VWD that, in the
             Investigator's opinion, would preclude participation in the study due to the possible
             increased risk of bleeding associated with the requirement to withhold prophylaxis
             during the study.
        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.

Updated on 09 Mar 2024. Study ID: NCT04770935